Virios Therapeutics

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Virios Therapeutics advances Long-COVID treatment, seeks strategic partnerships

Virios Therapeutics is on track with its Long-COVID Phase II study, showing promising results and a clear path towards value creation.
The company's focus on intellectual property protection and partnership development positions it well for long-term growth and innovation in the healthcare sector.
While facing challenges in study outcomes and partnership acquisitions, Virios remains proactive in seizing opportunities to enhance shareholder value and expand its treatment portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions a

Virios Therapeutics, Inc. Announces Closing of Public Offering

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Virios Therapeutics, Inc. Announces Pricing of Public Offering

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The Company intends to use the net proceeds from the offering primarily to further advan

Virios Therapeutics, Inc. Announces Proposed Public Offering

Source: Shutterstock / PopTika Virios Therapeutics (NASDAQ: VIRI ) stock is falling hard on Monday after the company revealed results from its Phase 2b Study of IMC-1 in Fibromyalgia. IMC-1 is a treatment in development by the company for people suffering from Fibromyalgia.

Why Is Virios Therapeutics (VIRI) Stock Down 71% Today?

Shares of Virios Therapeutics Inc. VIRI, +13.02% tumbled 64.3% in premarket trading on Monday after the company said its experimental fibromyalgia treatment did not meet the primary endpoint in a Phase 2b clinical trial. "Overall, the efficacy data from this trial were not what we had expected," R.

Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study of oral IMC-1 for the treatment of FM. Overall, the FORTRESS study did not achieve statistica

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced commencement of enrollment in its exploratory Long-COVID trial. This study is supported via an unrestricted investigational grant to the Bateman Horne Center, a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and tr

Virios Therapeutics' Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET CompanyParticipants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright & Co., LLC Operator Good morning, and welcome to the Virios Therapeutics, Inc. Second Quarter 2022 Financial Results Conference Call.

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q2 2022 Results - Earnings Call Transcript

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the second quarter ended June 30, 2022. Key Highlights and Upcoming Milestones Completed patient dosing in Phase 2b FORTRESS fibromyalgia study Top line FORTRESS results expected in September 2022 “Data published earlier this ye

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Q3 Virtual Investor Summit. During the presentation, the Company will provide an overview of its business and corporate strategy as well as upcoming ke

Virios Therapeutics, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

Company's September Phase 2b trial results could be transformative for fibromyalgia patientsNew York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and development of compelling clinical assets for multiple categories of viruses.

Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its second quarter 2022 financial results will be reported on Thursday, August 11, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m. ET to discuss the results

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022

Armed with near-term catalyst, VIRI is poised for next growth stageNew York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Development-stage biotechnology company Virios Therapeutics (NASDAQ: VIRI) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of Fibromyalgia (FM), a catalyst the company believes is related to activation of previously dormant herpes virus infection.

Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment

New York, New York--(Newsfile Corp. - July 19, 2022) - PCG Digital -- With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia ("FM"), Virios Therapeutics (NASDAQ: VIRI) anticipates Phase 2b results for its lead treatment candidate, oral IMC-1, in September. Virios TherapeuticsTo view an enhanced version of this graphic, please

Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced the results of a pilot study performed at the University of Alabama, titled “Gastric Herpes Simplex Virus Type 1 Infection is Associated with Functional Gastrointestinal Disorders in the Presence and Absence of Comorbid Fibromyalgia: A Pilot Case-Co

Virios Therapeutics' Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia

Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Angela Walsh - Senior Vice President of Finance, and Treasurer Greg Duncan - Chief Executive Officer Ralph Grosswald - Senior Vice President of Operations Conference Call Participants David Bautz - Zacks Research Operator Good morning, and welcome to the Virios Therapeutics, Incorporated First Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at the company's request.

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q1 2022 Results - Earnings Call Transcript

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced financial results for the first quarter ended March 31, 2022. Key Highlights Completed enrollment in Phase 2b FORTRESS fibromyalgia study with top line results expected in September 2022 Targeting completion of chronic toxicology studies concurrent

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets. Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m. ET to discuss the results and pro

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it has completed enrollment in its Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study, which is a randomized, double-blind evaluation of IMC-1 in patients with fi

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia

Virios Therapeutics' (VIRI) CEO Greg Duncan on Q4 2021 Results - Earnings Call Transcript

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases including fibromyalgia, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key Highlights Phase 2b FORTRESS fibromyalgia study top line results on track for Q3 2022 Chronic toxicology studies, required for IMC-1 Phase 3 studies, are progressing as planned and synchronize

Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 17, 2022 before the open of the financial markets. Management will also host a webcast and conference call on March 17, 2022 at 8:30 a.m. ET to discuss the results and provide a

Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference on Monday, March 14, 2022 at 10:00 a.m. PT. The session will focus on Virios' combination antiviral therapeutic approach, progress in advancing its

Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022

ATLANTA--(BUSINESS WIRE)---- $VIRI #COVID--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today a collaboration with the Bateman Horne Center (“BHC”) of Salt Lake City, Utah, to explore the role of combination antiviral therapy in Long COVID, otherwise known as Post-Acute Sequelae of COVID-19 . The Bateman Horne Center is a non-profit, interdisciplinary Center of Excel

Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a

News for Virios Therapeutics Stock (VIRI)